Literature DB >> 9379315

Osteopontin antisense deoxyoligonucleotides inhibit bone resorption by mouse osteoclasts in vitro.

N Tani-Ishii1, A Tsunoda, T Umemoto.   

Abstract

Osteopontin (OPN) is an acidic phosphoprotein synthesized by osteoblasts and osteoclastic cells that are localized in the mineralized phase of bone matrix. OPN is thought to bind to the vitronection receptor on the osteoclast membrane and regulates bone resorption by the osteoclast. In this study, we investigated whether or not OPN can relate to osteoclast differentiation and bone resorption in a co-culture system. When C57Black/6N mouse bone marrow cells suspended on ivory slices coated with collagen were inoculated onto a MC3T3-G2/PA6 cell layer, colonies containing TRAP(+) mononuclear and multinuclear cells were formed in the presence of 1 alpha, 25-dihydroxyvitamin D3 and dexamethasone. At the end of culture period the number of TRAP(+) osteoclast-like cells were counted and the resorption pits were evaluated by reflected light microscopy. The mRNA of OPN was detected by in situ hybridization. Osteoclast-like cells expressed OPN mRNA. The addition of an OPN antisense oligomer (5' AAT CAC TGC CAA TCT CAT 3') at the start of the co-culture period decreased the number of TRAP(+) cells present after 7 d (30.3 +/- 3.4 vs 56.9 +/- 12.4), and the ratio of mononuclear and multinucleated cells was changed (77.6:23.2 vs 60.8:39.3). The total area of pits per ivory slice was also decreased by adding the OPN antisense oligomer (246813 vs 303139 microns2). These results showed that OPN can be an important mechanism for regulating differentiation and bone resorption.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9379315     DOI: 10.1111/j.1600-0765.1997.tb00563.x

Source DB:  PubMed          Journal:  J Periodontal Res        ISSN: 0022-3484            Impact factor:   4.419


  4 in total

1.  Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435.

Authors:  Lalita A Shevde; Rajeev S Samant; Jason C Paik; Brandon J Metge; Ann F Chambers; Graham Casey; Andra R Frost; Danny R Welch
Journal:  Clin Exp Metastasis       Date:  2006-07-09       Impact factor: 5.150

2.  Col3.6-HSD2 transgenic mice: a glucocorticoid loss-of-function model spanning early and late osteoblast differentiation.

Authors:  Maobin Yang; Lorin B Trettel; Douglas J Adams; John R Harrison; Ernesto Canalis; Barbara E Kream
Journal:  Bone       Date:  2010-06-09       Impact factor: 4.398

3.  Protective role of osteopontin in endodontic infection.

Authors:  Susan R Rittling; Craig Zetterberg; Kader Yagiz; Stephen Skinner; Noriyuki Suzuki; Akira Fujimura; Hajime Sasaki
Journal:  Immunology       Date:  2009-09-11       Impact factor: 7.397

4.  Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression.

Authors:  M A Chellaiah; N Kizer; R Biswas; U Alvarez; J Strauss-Schoenberger; L Rifas; S R Rittling; D T Denhardt; K A Hruska
Journal:  Mol Biol Cell       Date:  2003-01       Impact factor: 4.138

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.